Dr. Teoh Phaik Ju (left) and Dr. Chooi Jing Yuan (right) at the 17th International Myeloma Workshop which took place on 12th – 15th September 2019 at the Hynes Convention Center in Boston MA, USA.
Congratulations to Dr. Teoh Phaik Ju and Dr. Chooi Jing Yuan, research fellows from Prof. Chng Wee Joo’s group who recently won awards to attend and present their research at the 17th International Myeloma Workshop (IMW) which took place from 12-15 September 2019. Held at the Hynes Convention Center in Boston MA, USA, IMW 2019 saw a strong turnout close to 3,200 attendees this year. The conference presents a unique platform for esteemed scientists and clinicians to exchange and obtain information on the latest breakthroughs in multiple myeloma and related plasma cell disorders.
Dr. Teoh with her award at the 17th IMW, which drew close to 3,200 attendees this year.
“It was a real eye-opening experience as the conference included numerous educational and plenary sessions featuring latest biological and clinical updates of the disease, and several keynote addresses by the big shots in the field highlighting the loopholes in the knowledge of myeloma and the things to focus on moving forward. This conference really showcased how the myeloma community is tightly-knitted with scientists and clinicians all over the world showing great eagerness in exchanging information and even forging potential collaborations. I have learned so much and am truly honoured to be part of their wall of fame.” Dr Teoh expressed.
Dr. Chooi (left) and Dr. Teoh (right) with their supervisor, Prof. Chng Wee Joo at the conference venue.
Dr. Chooi ‘s and Dr. Teoh’s abstracts titled “REIIBP is a histone methyltransferase overexpressed in T(4;14) multiple myeloma with oncogenic potential” and “Synthetic lethality in multiple myeloma harbouring double oncogenic hits of 17p13(del) and 1q21(amp)” respectively have won them the “IMS Award for Exemplary Abstract” award. They were among the 40 young investigator award recipients whose research have made significant advances in myeloma research.